E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion

Cedars-Sinai Medical Center logo

Cedars-Sinai Medical Center

Status

Terminated

Conditions

Coronary Artery Disease
Myocardial Perfusion

Treatments

Other: Cigarettes
Other: E-cigarettes (nicotine free e-liquid)
Other: E-cigarettes (low nicotine e-liquid)
Other: E-cigarettes (high nicotine e-liquid)

Study type

Interventional

Funder types

Other

Identifiers

NCT02612701
Pro00041957

Details and patient eligibility

About

E-cigarettes deliver nicotine by creating an aerosol of ultrafine particles. Many questions remain about the size and composition and especially about the potential toxicity of these particles. Thus, a key unanswered question-and the research question proposed-is whether e-cigarette aerosol triggers the same acute impairment in coronary microvessel function as does conventional cigarette smoke, which delivers a very well-defined exposure to fine particles and many fold greater exposure to toxic (combustion) products including volatile organic compounds (such as acrolein) that have been implicated in the pathogenesis of tobacco-related coronary disease. Because the effects of nicotine on the human coronary microcirculation remain incompletely defined-with multiple potential vasodilator and vasoconstrictor actions each of which may vary by dose-we will determine the comparative effects of conventional cigarette smoke against e-cigarette aerosol with no nicotine, with low-dose nicotine, and with high-dose nicotine.

Enrollment

20 estimated patients

Sex

All

Ages

18 to 49 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age 18-49
  • Regular cigarette smoker defined as at least 1 pack year and ≥ 5/day
  • E-cigarette smoker defined as ≥ 1/week in the last 6 months.

Exclusion criteria

  • Sub-optimal echocardiography images as determined by the sonographer and/or investigators.
  • History of cardiopulmonary (including asthma or use of inhalers),
  • History of diabetes or dyslipidemia
  • History of psychiatric illness
  • Blood Pressure > 140/90
  • Body Mass Index ≤ 18.5 or ≥ 30 kg•m2
  • Evidence of any of the above by physical examination, Electrocardiogram (ECG) or echocardiogram
  • Resting Heart Rate > 100 beats/min
  • Cardiac rhythm disorder, specifically: rhythm other than sinus, Supraventricular Tachycardia (SVT), atrial fibrillation, ventricular tachycardia
  • Use of prescription medication except oral contraceptive pills
  • History of illicit drug use (self-stated)
  • Pregnant
  • Any other condition(s) deemed by the physician investigators that put subjects at risk for participating in the study

Trial design

Primary purpose

Other

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

20 participants in 4 patient groups

Cigarettes
Experimental group
Description:
Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking two standard cigarettes
Treatment:
Other: Cigarettes
E-cigarettes (nicotine free e-liquid)
Experimental group
Description:
Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking nicotine free e-cigarette liquid.
Treatment:
Other: E-cigarettes (nicotine free e-liquid)
E-cigarettes (low nicotine e-liquid)
Experimental group
Description:
Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking low concentration(4-6 mg/mL) e-cigarette liquid.
Treatment:
Other: E-cigarettes (low nicotine e-liquid)
E-cigarettes (high nicotine e-liquid)
Experimental group
Description:
Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking high concentration (18-24 mg/mL) e-cigarette liquid.
Treatment:
Other: E-cigarettes (high nicotine e-liquid)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems